CLRB Similar Chart Price Prediction
The price of CLRB is predicted to go up -18.15%, based on the high correlation periods with HLF. The similarity of these two price pattern on the periods is 96.35%.
CLRB
HLF
Down: -18.15%Similarity: 96.35%
CLRB Revenue Forecast
CLRB EPS Forecast
CLRB FAQs
What is bull’s view on CLRB?
What is bear's view on CLRB?
What is CLRB eps forecast for next quarter？
CLRB Analyst's Forecast
Jeff Jones
Oppenheimer
Buy
2024-11-19
Price Target
$14 → $12
Upside
+645.34%
Oppenheimer analyst Jeff Jones lowered the firm's price target on Cellectar Biosciences to $12 from $14 and keeps an Outperform rating on the shares after the company provided Q3 financial and business updates, with updated Iopofosine I131 data in WM being slated for an oral presentation at ASH on December 9th. Management also disclosed that discussions with the FDA around a likely to be required confirmatory trial are anticipated to delay the NDA filing from late Q4 2024 to late Q1 2025. While Oppenheimer remains confident in the ultimate approval, the firm updates its model for actuals, while adjusting timelines and adding a year-end 2024 financing.
